Lymphokines, E.g., Interferons, Interlukins, Etc. Patents (Class 530/351)
-
Patent number: 8242072Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.Type: GrantFiled: November 10, 2011Date of Patent: August 14, 2012Assignee: ZymoGenetics, Inc.Inventors: Steven D. Levin, Mark W. Rixon, Zeren Gao
-
Patent number: 8241629Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: December 17, 2010Date of Patent: August 14, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Publication number: 20120201831Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: March 9, 2012Publication date: August 9, 2012Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
-
Publication number: 20120197006Abstract: Modified interferon beta polypeptides and uses thereof are provided.Type: ApplicationFiled: January 6, 2012Publication date: August 2, 2012Applicant: AMBRX, INC.Inventors: Vadim KRAYNOV, Nick KNUDSEN, Anna-Maria A. HAYS PUTNAM, Denise KRAWITZ, Jason PINKSTAFF, Heather MYLER
-
Publication number: 20120196346Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different.Type: ApplicationFiled: March 14, 2012Publication date: August 2, 2012Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Patent number: 8231866Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.Type: GrantFiled: January 19, 2012Date of Patent: July 31, 2012Assignee: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Brian A. Fox, Kevin M. Klucher, David W. Taft, Wayne Kindsvogel
-
Patent number: 8231875Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.Type: GrantFiled: November 16, 2005Date of Patent: July 31, 2012Assignee: UCB Pharma S.A.Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
-
Patent number: 8232371Abstract: Modified interferon polypeptides with at least one non-naturally-encoded amino acid and uses thereof are provided.Type: GrantFiled: December 8, 2011Date of Patent: July 31, 2012Assignee: Ambrx, Inc.Inventors: Ho Sung Cho, Thomas O. Daniel, Anna-Maria A. Hays Putnam, Troy E. Wilson
-
Publication number: 20120190097Abstract: The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.Type: ApplicationFiled: September 8, 2010Publication date: July 26, 2012Inventors: Gerardo M. Castillo, Elijah M. Bolotin, Akiko Nashimoto-Ashfield
-
Publication number: 20120190631Abstract: Techniques to glycosylation are described, and more particularly to the production of glycosylation structures that are resistant to enzymatic degradation, thereby modulating one or more of their biological properties or those of therapeutic moieties incorporating them, and in particular to reacting activated carbohydrate substrates containing fluorine, such as 3-fluoro sialic acid compounds, with sugar acceptors to produce covalent conjugates of the sugar acceptor and one or more of the sialic acid compounds.Type: ApplicationFiled: June 16, 2010Publication date: July 26, 2012Inventors: Andrew Graham Watts, Amanda Barbara MacKenzie, Terrence Kantner
-
Publication number: 20120190096Abstract: The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water soluble fatty acid derivative under conditions that allow conjugation.Type: ApplicationFiled: December 16, 2011Publication date: July 26, 2012Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Juergen Siekmann, Richard Scheinecker, Hanspeter Rottensteiner, Peter Turecek
-
Patent number: 8227579Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: August 27, 2010Date of Patent: July 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, James W. West, Robert Mabry, Brent Meengs, Steven D. Levin
-
Patent number: 8226948Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: January 11, 2012Date of Patent: July 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Publication number: 20120183964Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: March 29, 2012Publication date: July 19, 2012Applicant: Schering CorporationInventor: J. Fernando Bazan
-
Publication number: 20120183495Abstract: The present invention provides avian CSF1 genes encoding proteins which bind avian colony stimulating factor 1 receptor (CSF1R) and which exhibit immunomodulatory properties.Type: ApplicationFiled: June 22, 2010Publication date: July 19, 2012Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGHInventors: David Arthur Hume, Dave Burt, David Sester, Valerie Garceau, Jacqueline Smith, Bob Paton
-
Patent number: 8221748Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.Type: GrantFiled: October 13, 2009Date of Patent: July 17, 2012Assignee: Baylor Research InstituteInventors: Jacques Banchereau, Virginia Pascual
-
Publication number: 20120177595Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.Type: ApplicationFiled: September 21, 2011Publication date: July 12, 2012Applicant: ALTOR BIOSCIENCE CORPORATIONInventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
-
Publication number: 20120177603Abstract: A method for the production of human glycosylated Interferon-beta (IFN-?) is described, comprising two affinity chromatography steps followed by hydrophobic interaction chromatography step preferably with a subsequent anion exchange chromatography step. IFN-? obtained by the method as described is characterized by a high purity and specific biologically activity, because of which it is particularly suitable for the production of pharmaceutical compositions.Type: ApplicationFiled: July 7, 2010Publication date: July 12, 2012Applicant: BioGenerix AGInventors: Stefan Arnold, Christian Scheckermann
-
Patent number: 8216583Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: August 15, 2003Date of Patent: July 10, 2012Assignee: Abbott Biotechnology, Ltd.Inventors: Hans-Juergen Kruase, Lisa Baust, Michael Dickes
-
Patent number: 8217008Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.Type: GrantFiled: October 7, 2010Date of Patent: July 10, 2012Assignee: ZymoGenetics, Inc.Inventors: Donald C. Foster, Wenfeng Xu, Karen L. Madden, James D. Kelly, Cindy A. Sprecher, Cameron S. Brandt, Mark W. Rixon, Scott R. Presnell, Brian A. Fox
-
Publication number: 20120174264Abstract: Methods of in vitro propagation of plants of the genus Eriodictyon are described, including, in particular embodiments, plants of the species E. californicum, E. trichocalyx and E. sessilifolium. Methods of producing transgenic plants of the genus Eriodictyon are also described, along with methods of producing recombinant proteins in such plants. Compositions and methods for administering recombinant proteins produced in these plants are also described.Type: ApplicationFiled: March 8, 2012Publication date: July 5, 2012Inventors: Hilary Koprowski, Natalia Pogrebnyak, Maxim Golovkin
-
Publication number: 20120164162Abstract: A method for the manufacture of products by biotechnological methods in bacterial cell culture is disclosed as well as products obtained, the use of certain additives to the media used in the manufacture of said products in bacterial cell culture media, and the use of said additives in reducing the detrimental effects of radicals in the manufacture of the products, as well as aspects related to these invention embodiments. The manufacturing process or method comprises adding one or more radical scavenging and/or antioxidative additive preferably selected from the group consisting of sterically hindered nitroxyls, sterically hindered hydroxylamines, sterically hindered hydroxylamine salt compounds, sterically hindered amino compounds and sterically hindered N-hydrocarbyloxyamines, benzofuranone compounds, as obligatory component(s) to the medium used during biosynthesis.Type: ApplicationFiled: August 11, 2010Publication date: June 28, 2012Applicant: BASF SEInventors: Franz Kaufmann, Trine Hefsgaard Miller, Johannes Flothmann, Beate Winter, Andreas Hafner
-
Publication number: 20120165508Abstract: The invention relates to fusion proteins comprising an amino acid sequence corresponding to an H fragment or an amino acid sequence corresponding to a calcium binding protein excreted-secreted by the adult worm of Fasciola hepatica, namely the proteins Fh8 and Fh22, followed by an amino acid sequence corresponding to an unrelated protein fragment or protein, and a process for the preparation thereof and their use in recombinant protein expression systems.Type: ApplicationFiled: December 10, 2009Publication date: June 28, 2012Inventors: Maria Antónia Pereira Da Conceição, Sofia Judite Marques Da Costa, António Manuel Oliveira Castro, André Augusto Da Silva Almeida
-
Publication number: 20120164101Abstract: A conjugate protein comprising a GM-CSF or fragment thereof linked to an IL-21 or fragment thereof is described. The conjugate protein has unexpected immune activating and tumoricidal properties and is useful in a variety of therapeutic applications.Type: ApplicationFiled: April 12, 2010Publication date: June 28, 2012Inventors: Jacques Galipeau, Patrick Williams
-
Patent number: 8207141Abstract: DNA plasmids containing sequences coding for different fragments of 185neu oncoprotein which are able to induce an immune response against p185neu-overexpressing tumors, and pharmaceutical compositions thereof are described.Type: GrantFiled: June 30, 2011Date of Patent: June 26, 2012Inventors: Augusto Amici, Cristina Marchini, Elena Quaglino, Federica Cavallo, Guido Forni
-
Patent number: 8206948Abstract: Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.Type: GrantFiled: August 26, 2005Date of Patent: June 26, 2012Assignee: Conaris Research Institute AGInventors: Dirk Seegert, Georg Wätzig, Nikolaus Rahaus, Jessica Daecke, Stefan Rose-John
-
Patent number: 8206712Abstract: Treatment of rheumatoid arthritis and osteoporosis using an anti-IL-20 antibody 7E, and optionally, in combination with an etanercept polypeptide.Type: GrantFiled: July 2, 2010Date of Patent: June 26, 2012Assignee: National Cheng Kung UniversityInventor: Ming-Shi Chang
-
Publication number: 20120148552Abstract: Integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor (CAR), such as the IL13R?2 specific IL13-zetakine (IL13?), enhances T cell-mediated responses against tumors even in the absence of expressed ligands for costimulatory receptors.Type: ApplicationFiled: August 26, 2009Publication date: June 14, 2012Applicant: CITY OF HOPEInventor: Michael Jensen
-
Publication number: 20120149650Abstract: The present invention relates to methods and compositions of modified variants of diphtheria toxin (DT) that reduce binding to vascular endothelium or vascular endothelial cells, and therefore, reduce the incidence of Vascular Leak Syndrome. One aspect of the present invention relates to a polypeptide toxophore from a modified DT, wherein the mutation is the substitution or deletion at least one amino acid residue at the amino acid residues 6-8, 28-30 or 289-291 of native DT. Another aspect of the present invention relates to a fusion protein which comprises a modified DT and a non-DT fragment. Another aspect of the present invention relates to the use of modified DT for the treatment of cancer.Type: ApplicationFiled: October 20, 2011Publication date: June 14, 2012Inventors: Robert J. Harrison, Johanna C. Vanderspek
-
Publication number: 20120148526Abstract: An immunogenic product includes TNF? coupled with KLH, wherein the TNF? is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the immunogenic product and methods for preparing the immunogenic product are also described.Type: ApplicationFiled: December 8, 2010Publication date: June 14, 2012Applicant: NEOVACSInventors: Géraldine GROUARD-VOGEL, Olivier DHELLIN, Bernard FANGET, Pierre VANDEPAPELIÈRE
-
Publication number: 20120142033Abstract: Extraction and purification of recombinant proteins rendered difficult to extract from transgenic plants by using an extraction solution containing reducing agents and surfactants or an extraction solution containing reducing agents and organic solvents.Type: ApplicationFiled: September 20, 2011Publication date: June 7, 2012Applicants: PrevenTec, Inc., National Institute of Agrobiological ScienceInventors: Yoshihiro Fujiwara, Kenji Sekikawa, Yasuhiko Aiki, Fumio Takaiwa, Lijun Yang
-
Publication number: 20120141415Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 29, 2007Publication date: June 7, 2012Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20120141416Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.Type: ApplicationFiled: June 30, 2010Publication date: June 7, 2012Applicant: Angiochem Inc.Inventors: Michel Demeule, Christian Che, Carine Thiot
-
Publication number: 20120142896Abstract: Modified interferon polypeptides with at least one non-naturally-encoded amino acid and uses thereof are provided.Type: ApplicationFiled: December 8, 2011Publication date: June 7, 2012Applicant: AMBRX, INC.Inventors: Ho Sung CHO, Thomas O. DANIEL, Anna-Maria A. HAYS, Troy E. WILSON
-
Publication number: 20120141505Abstract: Provided herein are CD19-ligand (CD19-L) polypeptides and polynucleotides encoding such CD19-L polypeptides. Methods related to diagnosing and treating a disorder associated with CD19 positive B-cells in a patient using a CD19-L polypeptide are also provided.Type: ApplicationFiled: October 31, 2011Publication date: June 7, 2012Inventor: Fatih M. Uckun
-
Patent number: 8193323Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: April 18, 1995Date of Patent: June 5, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8192955Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: May 25, 1994Date of Patent: June 5, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8193316Abstract: The subject invention relates generally to novel biologically active TACI-Fc fusion proteins that bind to BLyS and/or APRIL and uses thereof. The invention also relates to methods for recombinant production of homogeneous TACI-Fc fusion proteins on a large scale.Type: GrantFiled: December 15, 2009Date of Patent: June 5, 2012Inventors: Jianmin Fang, Zheng Liu
-
Patent number: 8192736Abstract: The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.Type: GrantFiled: October 28, 2005Date of Patent: June 5, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Etsuo Ohshima, Hirokazu Kawasaki, Naoya Kimoto, Akihiko Watanabe
-
Publication number: 20120134960Abstract: A recombinant human interferon-alpha mutein that contains at least one glycosylation site at a position of its amino acid sequence that is a part of an alpha helix-type secondary structure, a gene encoding the mutein, a method for producing the gene, a method for obtaining an eukaryotic cell producing the mutein, a method for producing the mutein, a process for purifying the mutein, a pharmaceutical composition containing the mutein, and the use of the mutein for manufacturing a medicament.Type: ApplicationFiled: June 15, 2007Publication date: May 31, 2012Applicants: Protech Pharma, S.A.Inventors: Ricardo Agustin Lopez, Natalia Analia Ceaglio, Marina Etcheverrigaray, Marcos Rafael Oggero Eberhardt, Ricardo Kratje
-
Publication number: 20120134961Abstract: Disclosed is an interferon-? (IFN-?) fused protein having IFN-? fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-?, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses.Type: ApplicationFiled: March 27, 2009Publication date: May 31, 2012Applicant: JW Pharmaceutical CorporationInventors: Chan Kyu Lee, Seonyoung Yang, Ju Kang, Kang Ryu, Hyun Soo Lee, Yong Soo Bae
-
Publication number: 20120134957Abstract: The present invention relates to a purified nucleic acid sequence encoding a homologue of human interleukin 10 (IL-10), wherein said IL-10 homologue is expressed during the latent phase of infection by a virus of the herpesvirideae group. The present invention also relates to uses of this polypeptide, in particular for diagnosing disease states and screening for modulator and inhibitor compounds of such polypeptides and in turn the virus itself, screening for infection in vertebrates and biological tissue, cleansing of infected biological tissues, and in the treatment and/or prophylaxis and/or diagnosis of disease caused by a virus of the herpesvirideae group.Type: ApplicationFiled: November 29, 2011Publication date: May 31, 2012Applicant: THE UNIVERSITY OF SYNDEYInventors: BARRY SLOBEDMAN, ALLISON DENISE ABENDROTH, CHRISTINA ANNE JENKINS
-
Patent number: 8187584Abstract: The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.Type: GrantFiled: August 8, 2011Date of Patent: May 29, 2012Assignees: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Tadanori Mayumi, Yasuo Tsutsumi, Shinsaku Nakagawa, Tsunetaka Ohta
-
Publication number: 20120128629Abstract: A method of site specific labelling of an interferon molecule is provided. The method comprises the steps: a) providing a label molecule comprising a PEG moiety having an aldehyde or ketone moiety; b) providing an interferon molecule having a C terminal hydrazide moiety; and c) allowing the aldehyde or ketone moiety of the PEG moiety to react with the C terminal hydrazide of the interferon molecule to form a labelled interferon molecule, which comprises a PEG moiety attached to the C terminus of the interferon molecule via a hydrazone bond. Interferon molecules labelled using such a method are also described.Type: ApplicationFiled: May 17, 2010Publication date: May 24, 2012Applicant: Almac Sciences (Scotland) LimitedInventors: Jennifer Roberts, Graham Cotton
-
Patent number: 8182803Abstract: The present invention provides biologically active variants of human ?-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human ?-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human ?-2b-interferon. The invention encompasses these biologically active variant ?-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant ?-interferon polypeptides and a pharmaceutically acceptable carrier.Type: GrantFiled: May 11, 2011Date of Patent: May 22, 2012Assignee: Biolex Therapeutics, Inc.Inventors: Lynn Dickey, John Gasdaska, Kevin Cox
-
Patent number: 8182814Abstract: The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11.Type: GrantFiled: October 23, 2008Date of Patent: May 22, 2012Assignees: CSL Limited, Yale UniversityInventors: Manuel Baca, Andrew Donald Nash, Jack A. Elias
-
Publication number: 20120124683Abstract: The present invention relates, in general, to siRNA and, in particular, to a method of effecting targeted delivery of siRNAs and to compounds suitable for use in such a method.Type: ApplicationFiled: June 29, 2011Publication date: May 17, 2012Applicant: DUKE UNIVERSITYInventors: Bruce A. Sullenger, Paloma H. Giangrande, James McNamara
-
Patent number: 8178107Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: April 18, 1995Date of Patent: May 15, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8178082Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: December 14, 2010Date of Patent: May 15, 2012Assignee: Genentech, Inc.Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
-
Patent number: 8178308Abstract: Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists and antagonists. Also provided are methods of treatment of immune and proliferative disorders.Type: GrantFiled: May 18, 2007Date of Patent: May 15, 2012Assignee: Schering CorporationInventors: Rene de Waal Malefyt, Marilyn Travis, Elena Vaisberg